Since Fkbp12 knockdown protected from C26 cancer cells-induced muscle atrophy (Figures 2C and 2J–2M) and that BMP signaling is decreased in cancer-related skeletal muscle atrophy14 (Figure 1B), we decided to bypass the inhibition of the BMP signaling using a pharmacological approach (Figure 3A). This evidence concerns the gene FKBP1A and cancer.